The Journal of Rheumatology
-
Publication Venue For
-
Development and Initial Validation of a Systemic Lupus Erythematosus-Specific Measure of the Extent of and Reasons for Medication Nonadherence..
49:1341-1348.
2022
-
How to Provide Sexual and Reproductive Health Care to Patients: Focus Groups With Rheumatologists and Rheumatology Advanced Practice Providers.
2022
-
Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
2022
-
Pediatric to Adult Transition Literature: Scoping Review and Rheumatology Research Prioritization Survey Results..
49:1201-1213.
2022
-
Development of an Item Bank for a Health-Related Quality of Life Measure in Spondyloarthritis..
49:1006-1011.
2022
-
Association of Health Literacy and Numeracy With Lupus Knowledge and the Creation of the Lupus Knowledge Assessment Test..
49:585-591.
2022
-
Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group..
49:20-25.
2022
-
Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)..
49:1-3.
2022
-
Promoting Diversity, Equity, and Inclusion for Psoriatic Diseases..
49:48-51.
2022
-
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America..
49:607-614.
2022
-
COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance..
49:110-114.
2022
-
Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study..
48:1856-1862.
2021
-
Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis..
48:1547-1551.
2021
-
Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry..
48:1322-1329.
2021
-
Racial Differences in Patient-provider Communication, Patient Self-efficacy, and Their Associations With Systemic Lupus Erythematosus-related Damage: A Cross-sectional Survey..
48:1022-1028.
2021
-
Biomechanical Factors May Be the Main Contributor to Entheseal Changes in Normal Adults..
48:618-619.
2021
-
Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis..
48:567-574.
2021
-
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.
2021
-
Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City..
48:454-462.
2021
-
Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis..
48:58-66.
2021
-
Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study..
48:114-122.
2021
-
Dr. Balevic, et al reply..
47:1587.
2020
-
Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma..
47:1242-1252.
2020
-
Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.
2020
-
Juvenile Dermatomyositis and Development of Malignancy: 2 Case Reports and a Literature Review..
47:479.
2020
-
Is Traditional Chinese Medicine Use Associated with Worse Patient-reported Outcomes among Chinese American Rheumatology Patients?.
46:1634-1639.
2019
-
Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis..
46:1164-1167.
2019
-
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials..
46:1173-1178.
2019
-
Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report..
46:996-1005.
2019
-
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials..
46:990-995.
2019
-
Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis..
46:455-459.
2019
-
It Is Time to Modify Treatment to Enable More Women with Rheumatoid Arthritis to Have Successful Pregnancies..
46:223-225.
2019
-
Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes..
46:57-63.
2019
-
Preconceptional Cardiovascular Health and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus..
46:70-77.
2019
-
New Features for Measuring Disease Activity in Pediatric Localized Scleroderma..
45:1680-1688.
2018
-
The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting.
45:52-53.
2018
-
Adiposity in Juvenile Psoriatic Arthritis..
45:411-418.
2018
-
Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report..
44:1894-1898.
2017
-
Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group..
44:1916-1919.
2017
-
Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016..
44:1889-1893.
2017
-
Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group..
44:1727-1733.
2017
-
Malignancy in Pediatric-onset Systemic Lupus Erythematosus..
44:1484-1486.
2017
-
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016..
44:1522-1528.
2017
-
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group..
44:697-700.
2017
-
Proceedings of the GRAPPA 2016 Retreat..
44:668-673.
2017
-
Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting..
44:703-705.
2017
-
Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash..
44:110-116.
2017
-
Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis..
44:117-124.
2017
-
The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013..
43:1755-1762.
2016
-
Identifying Targets for Improving Mental Healthcare of Adolescents with Systemic Lupus Erythematosus: Perspectives from Pediatric Rheumatology Clinicians in the United States and Canada..
43:1136-1145.
2016
-
Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting..
43:970-973.
2016
-
Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting..
43:965-969.
2016
-
Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12..
43:203-207.
2016
-
The Performance and Association Between Patient-reported and Performance-based Measures of Physical Functioning in Research on Individuals with Arthritis..
43:131-137.
2016
-
Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls..
42:2419-2426.
2015
-
Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol..
42:2270-2278.
2015
-
Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures..
42:2448-2459.
2015
-
Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014..
42:2198-2203.
2015
-
Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective..
42:1971-1975.
2015
-
Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda..
42:1934-1942.
2015
-
Building bridges between researchers and patient research partners: A report from the grappa 2014 annual meeting.
42:1021-1026.
2015
-
Review of the psoriatic arthritis working group at OMERACT 12: A report from the GRAPPA 2014 annual meeting.
42:1048-1051.
2015
-
The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive..
42:363-371.
2015
-
Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis..
41:2459-2465.
2014
-
Erratum: Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept (Journal of Rheumatology (2005) 32 (740-743)).
41:2336.
2014
-
Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study..
41:2129-2136.
2014
-
Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis..
41:1974-1979.
2014
-
Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors..
41:1163-1170.
2014
-
Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting..
41:1206-1211.
2014
-
Associations between biomarkers of joint metabolism, hand osteoarthritis, and hand pain and function: the Johnston County Osteoarthritis Project..
41:938-944.
2014
-
Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11..
41:782-791.
2014
-
Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis..
40:1200-1211.
2013
-
Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate..
40:741-742.
2013
-
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial..
40:455-460.
2013
-
BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies..
40:294-302.
2013
-
Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis..
40:127-136.
2013
-
Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry..
39:2341-2351.
2012
-
The Myositis Activities Profile -- initial validation for assessment of polymyositis/dermatomyositis in the USA..
39:2134-2141.
2012
-
Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions..
39:2012-2020.
2012
-
Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis..
39:1687-1697.
2012
-
Assessing the performance of the Birmingham Vasculitis Activity Score at diagnosis for children with antineutrophil cytoplasmic antibody-associated vasculitis in A Registry for Childhood Vasculitis (ARChiVe)..
39:1088-1094.
2012
-
How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom?.
39:1056-1063.
2012
-
Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis (Journal of Rheumatology (2012) 39, (510-515)).
39:881.
2012
-
Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis..
39:510-515.
2012
-
Racial differences in knee osteoarthritis pain: potential contribution of occupational and household tasks..
39:337-344.
2012
-
Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis..
38:1048-1054.
2011
-
The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus..
38:1012-1016.
2011
-
Platelet microparticles: making blood a bad humor..
38:590-592.
2011
-
Autoimmune disease incidence among women prenatally exposed to diethylstilbestrol..
37:2167-2173.
2010
-
Hazard of incident and progressive knee and hip radiographic osteoarthritis and chronic joint symptoms in individuals with and without limb length inequality..
37:2133-2140.
2010
-
Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey..
37:1953-1961.
2010
-
Associations of occupational tasks with knee and hip osteoarthritis: the Johnston County Osteoarthritis Project..
37:842-850.
2010
-
Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens..
37:870-875.
2010
-
HMGB1: a dangerous player in lupus pathogenesis..
37:689-691.
2010
-
Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine..
36:2724-2732.
2009
-
The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures..
36:2819-2829.
2009
-
Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis..
36:2264-2268.
2009
-
Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis..
36:2224-2230.
2009
-
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design..
36:1792-1799.
2009
-
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria..
36:1785-1791.
2009
-
Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers..
36:1769-1784.
2009
-
Current therapies for lupus nephritis in an ethnically heterogeneous cohort..
36:298-305.
2009
-
Bone scanning of limited value for diagnosis of symptomatic oligofocal and multifocal osteonecrosis..
35:1629-1634.
2008
-
Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis..
35:1680-1681.
2008
-
Osteoarthritis and sleep: the Johnston County Osteoarthritis Project..
35:1102-1107.
2008
-
Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota..
35:445-447.
2008
-
The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event..
34:2446-2450.
2007
-
Association of anemia and physical disability among patients with rheumatoid arthritis..
34:2177-2182.
2007
-
The value of measuring variability in osteoarthritis pain..
34:2132-2133.
2007
-
Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate..
34:1817-1822.
2007
-
Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis..
34:1465-1474.
2007
-
Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations..
34:1027-1031.
2007
-
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials..
34:634-640.
2007
-
Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis..
34:466-468.
2007
-
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein..
34:623-633.
2007
-
Influence of oxygen tension on interleukin 1-induced peroxynitrite formation and matrix turnover in articular cartilage..
34:401-407.
2007
-
Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy..
33:1392-1394.
2006
-
A boy with fever and whorl keratopathy..
33:1210-1211.
2006
-
Precocious osteoarthritis in a family with recurrent COL2A1 mutation..
33:1133-1136.
2006
-
Arthritis prevalence and symptoms among US non-veterans, veterans, and veterans receiving Department of Veterans Affairs Healthcare..
33:348-354.
2006
-
Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis..
32:2116-2124.
2005
-
Erratum: Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: Face validity of self-report questionnaire ratings (Journal of Rheumatology (2005) 32 (533-539)).
32:966.
2005
-
Kidney disease other than renal crisis in patients with diffuse scleroderma..
32:649-655.
2005
-
Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept..
32:740-743.
2005
-
Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: face validity of self-report questionnaire ratings..
32:533-539.
2005
-
Warfarin in antiphospholipid syndrome--time to explore new horizons..
32:208-212.
2005
-
High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward..
31:2331-2335.
2004
-
Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis..
31:2529-2530.
2004
-
Occupational risk factors for the development of systemic lupus erythematosus..
31:1928-1933.
2004
-
N-acetyl transferase genotypes in relation to risk of developing systemic lupus erythematosus..
31:76-80.
2004
-
Nonsteroidal antiinflammatory drug toxicity monitoring and safety practices..
30:2680-2688.
2003
-
Racial differences in health care utilization among patients with osteoarthritis..
30:2201-2206.
2003
-
Surgical management of the rheumatoid hand: consensus and controversy among rheumatologists and hand surgeons..
30:1464-1472.
2003
-
Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis..
30:1341-1343.
2003
-
B cell loss leading to remission in severe systemic lupus erythematosus..
30:412-414.
2003
-
Glutathione S-transferase M null homozygosity and risk of systemic lupus erythematosus associated with sun exposure: a possible gene-environment interaction for autoimmunity..
30:276-282.
2003
-
Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis..
30:394-400.
2003
-
Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in african-americans..
30:60-67.
2003
-
Frequency of abnormal hand and wrist radiographs at time of diagnosis of polyarticular juvenile rheumatoid arthritis..
29:2214-2218.
2002
-
Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis..
29:667-677.
2002
-
Chronic widespread musculoskeletal pain with or without fibromyalgia: psychological distress in a representative community adult sample..
29:588-594.
2002
-
Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s..
29:309-316.
2002
-
Lack of association between juvenile idiopathic arthritis and fas gene polymorphism..
29:166-168.
2002
-
Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus..
28:2653-2656.
2001
-
Autologous stem cell transplantation for pediatric rheumatic diseases..
28:2337-2358.
2001
-
Risk factors associated with thrombosis in patients with antiphospholipid antibodies..
28:2018-2024.
2001
-
Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases..
28:1116-1120.
2001
-
Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women..
28:996-1003.
2001
-
Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group..
28:1106-1111.
2001
-
Effects of inherited thrombophilic mutations in an adolescent with antiphospholipid syndrome and systemic lupus erythematosus..
28:370-372.
2001
-
A general population study of fibromyalgia tender points in noninstitutionalized adults with chronic widespread pain..
27:2677-2682.
2000
-
Treatment of rheumatoid arthritis with a DR4/1 peptide..
27:1855-1863.
2000
-
Serum levels of soluble CD44 in primary Sjögren's syndrome..
27:1444-1449.
2000
-
Things do not get better by being left alone. The physician and complementary medicine..
27:1332-1333.
2000
-
Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy..
27:841-850.
2000
-
Perspectives on posttraumatic fibromyalgia: a random survey of Canadian general practitioners, orthopedists, physiatrists, and rheumatologists..
27:790-796.
2000
-
Prominent expression of mRNA for proinflammatory cytokines in synovium in patients with juvenile rheumatoid arthritis or chronic Lyme arthritis..
27:497-503.
2000
-
Familial dermatomyositis..
26:2691-2692.
1999
-
Specificity of antibodies to bacterial DNA in the sera of healthy human subjects and patients with systemic lupus erythematosus..
26:1934-1938.
1999
-
The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls..
26:1577-1585.
1999
-
The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario..
26:1570-1576.
1999
-
Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD..
26:816-825.
1999
-
Testing an instrument to screen for fibromyalgia syndrome in general population studies: the London Fibromyalgia Epidemiology Study Screening Questionnaire..
26:880-884.
1999
-
The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada..
26:885-889.
1999
-
Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus..
25:2364-2370.
1998
-
A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis..
25:1472-1479.
1998
-
Nitric oxide--friend or foe in arthritis?.
25:1451-1453.
1998
-
Immunogenetic studies in families of children with juvenile dermatomyositis..
25:1000-1002.
1998
-
Anti-DNA antibodies in systemic lupus erythematosus: a case of mistaken identity?.
25:195-197.
1998
-
Transforming growth factor-beta 1 and 2 in the synovial-like interface membrane between implant and bone in loosening of total hip arthroplasty..
24:694-701.
1997
-
Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo..
23:1856-1861.
1996
-
A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels..
23:654-658.
1996
-
The fibromyalgia syndrome: a consensus report on fibromyalgia and disability..
23:534-539.
1996
-
Transcranial doppler sonography to monitor cerebral vasculitis..
23:561-563.
1996
-
Potential pathogenicity of deglycosylated IgG cross reactive with streptokinase and fibronectin in the serum of patients with rheumatoid arthritis..
23:44-51.
1996
-
Breast feeding and the development of juvenile rheumatoid arthritis..
22:1166-1170.
1995
-
Fibromyalgia in rheumatology practice: a survey of Canadian rheumatologists..
22:722-726.
1995
-
Measuring shoulder function with the Shoulder Pain and Disability Index..
22:727-732.
1995
-
Cooccurrence of collagenous colitis with seronegative spondyloarthropathy: report of a case and literature review..
20:2153-2157.
1993
-
The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8..
20:1857-1862.
1993
-
Presentation of multicentric Castleman's disease with sicca syndrome, cardiomyopathy, palmar and plantar rash..
20:1588-1591.
1993
-
A randomized controlled trial of home exercise on the rheumatoid hand..
20:785-789.
1993
-
Diagnosis of crystal induced arthritis by dark field microscopy..
20:921-924.
1993
-
Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review..
19:1462-1465.
1992
-
Generic versus disease specific health status measures: comparing the sickness impact profile and the arthritis impact measurement scales..
19:543-546.
1992
-
Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate..
18:1741-1743.
1991
-
Large vessel vasculitis of the central nervous system in systemic lupus erythematosus: report and review of the literature..
18:748-751.
1991
-
Discrimination of antineutrophil antibodies from antinuclear antibodies using immunofluorescence on neutrophils and HL60 cells..
18:575-579.
1991
-
Serum immunoglobulin levels in systemic lupus erythematosus: the effects of age, sex, race and disease duration..
18:540-544.
1991
-
The relationship between soluble interleukin 2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus..
18:235-240.
1991
-
Mixed connective tissue disease with arterial thrombosis, antiphospholipid antibodies and heparin induced thrombocytopenia..
17:1523-1524.
1990
-
Clinical rheumatology training of primary care physicians: the resident perspective..
17:666-672.
1990
-
Patterns of autoantibody expression in pediatric and adult systemic lupus erythematosus..
16:1329-1334.
1989
-
Reduction of indomethacin induced gastroduodenal mucosal injury and gastrointestinal symptoms with cimetidine in normal subjects..
16:1249-1252.
1989
-
Antidouble stranded DNA antibody assays in systemic lupus erythematosus: correlations of longitudinal antibody measurements..
16:609-613.
1989
-
Early detection of carpal erosions in patients with rheumatoid arthritis: a pilot study of magnetic resonance imaging..
15:1361-1366.
1988
-
The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus..
15:1389-1394.
1988
-
Ureaplasma urealyticum septic arthritis in hypogammaglobulinemia..
15:369-371.
1988
-
Bilateral silicone induced synovitis of the wrist..
14:1202-1205.
1987
-
Pyomyositis and polyarticular septic arthritis from Hemophilus influenzae in a nonimmunocompromised adult..
14:1190-1192.
1987
-
The assessment of pain in rheumatoid arthritis: disease differentiation and temporal stability of a behavioral observation method..
14:700-704.
1987
-
Aspergillus flavus: an unusual cause of chest wall inflammation in an immunocompetent host..
13:660-662.
1986
-
Septic arthritis due to Micrococcus luteus..
13:659-660.
1986
-
Pectoralis pyomyositis: an unusual cause of chest wall pain in a patient with diabetes mellitus and rheumatoid arthritis..
13:434-436.
1986
-
Reticuloendothelial system fc receptor function in rheumatoid arthritis..
10:550-557.
1983
-
Independent expression of autoantibodies in systemic lupus erythematosus..
9:691-695.
1982
-
Characterization and comparison of commercially available antinuclear antibody kits using single pattern index sera..
7:339-347.
1980
-
Rheumatoid nodulosis. Sporadic and familial diseases..
6:286-292.
1979
-
COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance
2022
-
Differences in Healthcare Transition Views, Practices, and Barriers Among North American Pediatric Rheumatology Clinicians From 2010 to 2018.
2021
-
Real-world Clinical Profiles of Adults With Hypophosphatasia (HPP) from the Global HPP Registry
2021
-
Association of Poverty Income Ratio with Physical Functioning in a Cohort of Patients with Systemic Lupus Erythematosus.
2020
-
Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group.
2011
-
Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response
2010
-
Safety Update on Certolizumab Pegol (CZP) in Patients with Active Rheumatoid Arthritis (RA)
2010
-
The Efficacy of Certolizumab Pegol Added to Methotrexate is Sustained Over 2 Years in the Treatment of Rheumatoid Arthritis
2010
-
Certolizumab Pegol Inhibits Radiographic Progression at 16 Weeks of Treatment. Results from Two RCTs (RAPID 1 And 2)
2009
-
Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome.
2009
-
Inhibition of Progression of Structural Damage by Week 16 with Certolizumab Pegol: Results from the RAPID Trials
2009
-
Fibromyalgia syndrome.
2007